Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

In a report released today, Larry Biegelsen from Wells Fargo maintained a Hold rating on Johnson & Johnson (JNJ – Research Report).

In a report released today, Joanne Wuensch from Citi reiterated a Buy rating on Johnson & Johnson (JNJ – Research Report). The ...

The pro dancer also previews her partnership with Joey Graziadei, saying the Bachelor is 'humble and hardworking.' ...

By Mike Spector and Dietrich Knauth (Reuters) -Johnson & Johnson plans to pay an additional $1.1 billion to resolve tens of ...

A state judge in Oregon has overturned a $260 million verdict against Johnson & Johnson in a mesothelioma lawsuit. The judge ...

Johnson & Johnson ($JNJ) is escalating its efforts to resolve the long-running talc lawsuit by agreeing to pay an additional ...

Johnson & Johnson is regaining momentum with strong growth in its Innovative Medicine and MedTech segments, driven by new products and strategic acquisitions. The company’s robust financials ...

The healthcare-products company is taking another shot at resolving mass cancer lawsuits in chapter 11 after two failed ...

Johnson Controls (NYSE: JCI), the global leader for smart, healthy and sustainable buildings, is showcasing its industry ...

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Antiphospholipid Syndrome.

In June, Johnson & Johnson agreed to pay $700 million to settle an investigation by 42 states and Washington, D.C., into the marketing of talc-based products blamed for allegedly causing cancer.